M. Valladares

发表

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

C. García-Girón, J. García-Foncillas, J. Viéitez, 2011, Investigational New Drugs.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.

A. Carrato, E. Díaz-Rubio, M. Benavides, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

A. Carrato, V. Moreno, A. Abad, 2010, British Journal of Cancer.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer

A. Carrato, V. Moreno, G. Capellá, 2017, Molecular Cancer Therapeutics.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

G. Capellá, R. Salazar, D. Páez, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato, R. Salazar, C. García-Girón, 2021, Drugs & Aging.

AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy

Tae-You Kim, I. Láng, J. Douillard, 2008 .

A randomised, placebo-controlled, double-blind phase II study of raltitrexed and gefitinib vs raltitrexed alone as 2nd line chemotherapy in subjects with advanced colorectal cancer (CRC). GON group study (Grupo Oncologico del Norte)

C. García-Girón, J. García-Foncillas, J. Viéitez, 2007 .

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).

Cristina Santos, R. Goldberg, J. Tabernero, 2022, European journal of cancer.

Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition

Angélica Figueroa, L. Aparicio, V. Abella, 2013, Cellular and Molecular Life Sciences.

miR-203 Regulates Cell Proliferation through Its Influence on Hakai Expression

Angélica Figueroa, L. Aparicio, V. Abella, 2012, PloS one.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

C. Nadal, F. Rojo, R. López-López, 2019, Scientific Reports.

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

F. Rivera, M. Valladares, N. López-Martínez, 2017, Journal of medical economics.

Clinical implications of epithelial cell plasticity in cancer progression.

Angélica Figueroa, A. Concha, L. Calvo, 2015, Cancer letters.

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

A. Carrato, J. Tabernero, J. García-Foncillas, 2012, PloS one.

Management of hyperbilirubinaemia in pancreatic cancer patients.

A. Carrato, M. Hidalgo, T. Macarulla, 2018, European journal of cancer.

Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells

Angélica Figueroa, L. Aparicio, M. Valladares, 2014, BMC Cancer.

Biological influence of Hakai in cancer: a 10-year review

Angélica Figueroa, L. Aparicio, M. Valladares, 2012, Cancer and Metastasis Reviews.

Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma

A. Tres, X. G. Del Muro, J. Germá-Lluch, 2006, Melanoma research.

Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.

C. García-Girón, E. Esteban, R. López, 2003, Lung cancer.

A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

F. Rivera, C. Pericay, A. Irigoyen, 2010 .

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

R. Salazar, J. Aparicio, R. García-Carbonero, 2015, Clinical and Translational Oncology.

Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

A. Carrato, A. Abad, J. Maurel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition

Angélica Figueroa, L. Aparicio, V. Abella, 2013, Cellular and Molecular Life Sciences.

Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

R. López, R. Pérez-Carrión, J. Dorta, 2003, Medical oncology.

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.

A. Carrato, C. Köhne, P. Reichardt, 2013, European journal of cancer.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

A. Cebrián, C. Nadal, F. Rojo, 2019, Scientific Reports.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, F. Rivera, 2012, The oncologist.

A. Carrato, C. Köhne, P. Reichardt, 2013, European journal of cancer.